This month, CVS Caremark announced that it had also signed a deal to make Novo Nordisk’s Wegovy its preferred GLP-1RA ...

Zepbound will be excluded. This could complicate access to a drug that many patients cannot afford to pay for on their own. The formulary is maintained by CVS Health’s pharmacy benefits ...

The agreements cap patients’ monthly out-of-pocket costs for Zepbound and Wegovy at $200 and more deeply discount the drugs ...

5. In a blow to Eli Lilly’s Zepbound, CVS Caremark chose Novo Nordisk’s Wegovy as the preferred GLP-1 weight loss medication for its largest commercial template formularies. A CVS spokesperson said ...

CVS’s drug-benefits unit, known as Caremark, earlier this month negotiated a deal to make Novo’s Wegovy more widely available to its customers — knocking Eli Lilly & Co.’s Zepbound off its ...

Drugmakers are offering the blockbuster medications at steep discounts to people willing to pay out of pocket.

Shares in Eli Lilly have weakened after CVS Health, one of the largest pharmacy benefit managers (PBMs) in the US, said it would no longer cover its obesity therapy Zepbound. The shares closed ...

The new weight-loss option will cut what the plan sponsors pay as well as what the patients pay, Cigna’s PBM Evernorth says.

CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed by insurance that disrupt treatments for patients. By Rebecca Robbins ...

However, CVS Health recently announced that Wegovy will be the preferred option on its list of covered drugs starting July 1, while Zepbound won't be. "We're going to need to use them all just ...

The obesity drug helped patients reduce their waist size by an extra two inches compared to those on Novo Nordisk’s Wegovy in a head-to-head study of the two drugs.